Aligos Therapeutics Earnings Preview
Portfolio Pulse from Benzinga Insights
Aligos Therapeutics (NASDAQ:ALGS) is scheduled to release its quarterly earnings report on March 12, 2024, with analysts expecting an EPS of $-0.27. The company's past earnings performance shows a mix of beats and misses, with the share price reacting accordingly. Shares are currently trading at $0.8401, down 38.98% over the last 52 weeks. Investors will be keenly watching for not only the earnings results but also the company's guidance for future growth.
March 11, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Aligos Therapeutics is expected to report an EPS of $-0.27 for the upcoming quarter. Historical performance shows variability in beating EPS estimates, which has led to fluctuating stock prices. Currently, the stock is down 38.98% over the last year.
Given Aligos Therapeutics' mixed history of beating earnings estimates and the significant decline in its stock price over the past year, the upcoming earnings report could maintain the current stock price level if the company meets or exceeds the EPS estimate and provides positive future guidance. However, the stock's recent performance and the overall negative trend might limit significant upside potential in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100